Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: IV Acute myeloid leukaemia 12 mg/m2/day for 5 days to induce remission. Breast cancer; Liver cancer; Lymphoma; Prostate cancer Initial: 14 mg/m2, then repeat 3 wkly. Adjust subsequent doses based on degree of myelosuppression. As part of a combination regimen: May reduce initial dose to 10-12 mg/m2. Multiple sclerosis Initial: 12 mg/m2 once every 3 mth provided neutrophil count is >1,500 cells/mm3 and LVEF >50%.
Pregnancy and lactation. Multiple sclerosis with LVEF <50% or clinically significant reduction in LVEF.
Special Precautions
Preexisting myelosuppression. Perform periodic blood counts. Monitor cardiac function, especially after a cumulative dose of >160 mg/m2 and in patients with prior radiotherapy of the chest and concomitant cytotoxic therapy. Hepatic impairment. Discontinue admin if extravasation occurs. May impair ability to drive or operate machinery.
Adverse Reactions
Arrhythmia, oedema, ECG changes; pain, fatigue, fever, headache; alopecia, nail bed changes; amenorrhoea, menstrual disorder, hyperglycaemia; abdominal pain, anorexia, nausea, constipation, diarrhoea, GI bleeding, mucositis, stomatitis, dyspepsia, vomiting, wt gain/loss; abnormal urine, UTI; haematologic disorders; elevated LFTs; weakness; increased BUN and creatinine, haematuria; cough, dyspnoea, upper respiratory tract infection; fungal infection, infection, sepsis.
Potentially Fatal: Myelosuppression; cardiotoxicity.
Drug Interactions
Impaired immune response to vaccines may occur; infection after admin of live vaccines in patients on immunosuppressants is also possible.
ATC Classification
L01DB07 - mitoxantrone ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on mitoxantrone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in